We'll know more about the company's medium-term prospects by the end of the year.
Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...
Qatar has taken a landmark step in precision medicine after Sidra Medicine became the first hospital in the country — and one ...
Industry poised for growth, driven by advancements in precision drug discovery, rising gene therapy investments, and ...
Sidra Medicine, a member of Qatar Foundation, has been qualified by Vertex Pharmaceuticals as one of a of a limited number of ...
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
Key market opportunities include advancements in research, medicine, diagnostics, and biotechnology through CRISPR. There is potential for innovative solutions and ethical exploration in gene editing, ...
Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...
A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of regenerative medicine. The study, authored by ...
A trio of common amino acids may hold the key to unlocking far more powerful gene therapies. Researchers found that adding ...
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results